What is the current Humanized Mice Model market size?

Global Humanized Mice Model market size surpassed USD 280 million in 2023, driven by oncology and immuno-oncology R&D demand.

What growth is forecast through 2030?

Analysts project a 9–10% CAGR, pushing the Humanized Mice Model market past USD 530 million by 2030.

Which factors are key market drivers?

Rising cancer incidence, increased antibody therapeutic pipelines, government immuno-oncology grants, and CRISPR/Cas9 efficiency drive adoption.

What challenges restrain expansion?

Ethical scrutiny on animal use, high per-model cost, long production cycles, and stringent transport biosafety rules limit near-term uptake.

Which region leads adoption?

North America commands 48% share, fueled by NIH funds, major CROs, and CDER drug approvals requiring humanized data.

Who are the top companies?

Charles River, The Jackson Laboratory, Taconic Biosciences, Inotiv, genOway, and Cyagen lead, offering diverse immunodeficient backgrounds and IP portfolios.

What future opportunities exist?

Next-gen IL-15 or HLA-transgenic strains, patient-derived xenograft expansion, and personalized neoantigen screening create a compelling future outlook.

How is technology reshaping models?

CRISPR knock-ins shorten build time to weeks, while single-cell sequencing integration enables multi-omic profiling within the same humanized mice cohort.

What is the regulatory landscape?

FDA’s Predictive Toxicology Roadmap endorses humanized data, while ICH S6(R1) guides pre-species selection, accelerating IND submissions.

With immuno-oncology CAGR outpacing broader biotech and venture funding rebounding, stakeholders gain early-mover advantage in an under-supplied niche.

Humanized Mice Model Industry Trends & Competitive Analysis 2033

Humanized Mice Model by Application (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutions), by Types (Humanized Mouse Models, Humanized Rat Models), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Humanized Mice Model Market Overview

Humanized mice models are immune-deficient rodents engrafted with human genes, tissues, or peripheral blood cells, serving as indispensable pre-clinical surrogates for oncology, immunology, and infectious-disease research. The global Humanized Mice Model market size surpassed USD 280 million in 2024 and is forecast to accelerate at a double-digit CAGR of ~9% through 2033, underpinned by the growth outlook in personalized immuno-oncology, tightening FDA guidance on human-relevant data, and record venture funding into next-gen antibody and cell-therapy pipelines.

Loading chart…

North America continues to command the largest share (>40%) thanks to clustered CROs, biotech cash, and NIH budgetary uplifts, while China and India emerge as the fastest-expanding regional pockets—benefiting from lower vivarium costs, faster ethics approvals, and aggressive GLP capacity build-outs. Technology shifts toward IL-6 knock-in and triple-immune-checkpoint humanized strains, coupled with pricing pressure from in-house breeding by Big-Pharma, are reshaping competitive dynamics and forcing model vendors to bundle high-throughput pharmacodynamic assays and real-time bio-imaging services into long-term supply contracts.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	363.96 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ingenious Targeting Laboratory; Axen; rans Genic Inc.; Horizon Discovery Group PLC; HuMurine Technologies; Champions Oncology Inc.; Genoway S.A.; Crown Bioscience Inc.; Taconic Biosciences Inc.; The Jackson Laboratory; VitalstarBiotechnologyCo. Ltd.; Charles River Laboratories; Envigo; Jackson Laboratory; Psychogenics; Segnetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Oncology pipelines are shifting toward immuno-oncology bispecifics and cell therapies that require humanized mice for in-vivo proof-of-concept; sponsors now demand CDX/PDX-ready NSG derivatives, pushing Humanized Mice Model market volume CAGR above 14% and expanding the Humanized Mice Model market size beyond USD 180M in 2024.

FDA’s 2023 draft guidance pushes sponsors to validate immunogenicity and cytokine safety in humanized systems, making dual-humanized IL-6/IL-15 mice a regulatory “must have” rather than a nice-to-have, tightening supply and supporting double-digit price expansion through 2028.

Restraints

CRISPR-based multi-gene humanization (e.g., HLA-A2/IL-3/GM-CSF triple knock-in) extends breeding cycles to 9–10 months and pushes per-unit cost past USD 4,000, forcing CROs to share cohorts across studies and capping near-term Humanized Mice Model market penetration in mid-tier biotechs.

U.S. Department of Commerce is evaluating export-license requirements for certain immunodeficient strains under dual-use biosecurity rules; a 15- to 30-day clearance window would derail fast-turnaround GLP tox studies and compress growth forecast by ~230 bps in North America.

Opportunities

Emerging APAC CROs (China, Korea) offer humanized mouse PDX services at 35–40% cost advantage versus Taconic/Jackson; global sponsors can outsource large-scale efficacy panels, accelerating Humanized Mice Model market globalization and lifting the regional revenue share from 18% to 26% by 2027.

Rapid adeno-associated virus (AAV) vector programs for hemophilia and Duchenne require liver-humanized FRG mice; licensing this proprietary strain to gene-therapy sponsors yields recurring royalty streams (15–18% of service revenue) and raises segment gross margin by up to 500 bps.

Challenges

Supply chain for high-health-status human CD34+ stem-cell donors is concentrated in two U.S. blood centers; any contamination event triggers ≥6-month donor exclusion, jeopardizing study timelines and forcing model providers to hold costly 30% safety inventory.

Competitive landscape is fragmenting as university core facilities commercialize “home-brew” humanized strains at subsidized prices, eroding pricing discipline and threatening to compress overall Humanized Mice Model market ASPs by 4–6% annually through 2026.

Market Segmentation

Loading chart…

Application-based Humanized Mice Model segmentation reveals oncology commanding 38 % of 2023 demand, driven by rising syngeneic-human tumour co-engraftments that accelerate checkpoint inhibitor screens. Immunology and inflammation together account for 31 %; here, IL-2RG-NSG strains are indispensable for dissecting graft-versus-host or cytokine-release liabilities ahead of first-in-human trials. Infectious-disease programmes—hepatitis B, HIV, SARS-CoV-2—make up 19 %, leveraging human ACE2 or liver-liver chimeras to model pathogen life cycles when primate availability is restricted. Auto-immune, transplantation tolerance and rare-disease studies split the residual 12 %, but post-COVID grant inflows are pushing this share toward 15 % by 2026, illustrating how application breadth underpins total addressable market expansion.

Market taxonomy by type differentiates four substrata that shape unit economics and pricing tiers. CD34+ haematopoietic stem-cell models, priced > US $2 k per cohort, dominate long-term immunity studies because they sustain multi-lineage reconstitution (> 25 %) for ≥ 25 weeks. PBMC瞬时移植 versions, cheaper (< US $0.6 k) yet prone to lethal xenogeneic reactions, are reserved for 4–6 week T-cell functional assays. BLT (bone marrow–liver–thymus) constructs deliver the most robust human thymopoiesis, justifying > US $3 k pricing and 28 % YoY growth in immuno-oncology budgets. Finally, tissue-specific humanisation (liver, gut, CNS) occupies a boutique but expanding niche as sponsors seek organ-restricted PK/PD read-outs without full immune chimerism.

Humanized Mice Model Segmentation Breakdown7 items

Application

Pharmaceutical & Biotechnology Companies

Contract Research Organizations

Academic & Research Institutions

Types

Humanized Mouse Models

Humanized Rat Models

Regional Insights

Loading chart…

North America commands 42% of the Humanized Mice Model market, propelled by the NIH’s $2 bn translational immunotherapy grants, a dense cluster of CROs, and FDA mandates for humanized toxicology data. Asia Pacific is the fastest-growing region, posting 14.8% CAGR as China’s 14th Five-Year Plan earmarks $450 m for humanized rodent platforms and Japan’s PMDA accelerates regenerative-medicine approvals.

Europe (28% share) leverages Horizon Europe’s €1 bn cancer-mission budget, GDPR-compliant centralized biobanks, and the EMA’s adaptive-pathway pilot to expand humanized mice adoption in rare-disease studies.

Latin America (7% share) is scaling up through Brazilian CROs partnering with U.S. sponsors to meet local-content requirements, while Chilean biotechs tap government R&D tax credits to build humanized-mouse infrastructure.

Middle East & Africa (4% share) is nascent; however, Saudi Arabia’s NEOM $5 bn life-science zone and UAE genomic-medicine policies signal long-term Humanized Mice Model market growth potential beyond the 2030 regional forecast horizon.

Competitive Landscape

The Humanized Mice Model competitive landscape is moderately consolidated, with a handful of global contract research organizations and specialized transgenic boutiques sharing the addressable demand. Tier-1 suppliers (Charles River, The Jackson Laboratory, Crown Bioscience) leverage multi-continent production footprints and harmonized quality certifications (AAALAC, ISO 9001) to secure multi-year service agreements, while mid-size regional firms compete on price, short lead times, and local ethics board familiarity. Competitive levers center on breadth of genetic background inventory, flexibility in engraftment protocols, and documented reproducibility data rather than pure price, because downstream in-vivo failure costs remain the dominant buyer concern.

To escape commoditization pressure, vendors pursue targeted M&A (expanding immunodeficient substrains), risk-sharing partnerships with CDMOs, and incremental product launches centered on double or triple knock-in models. Differentiation is increasingly anchored in proprietary humanization technologies—such as adeno-associated virus or CRISPR/hSC–based platforms—and in value-added services (study design, bioinformatics, longitudinal sample logistics) that deepen stickiness. Margin compression persists because serum, housing, and compliance costs rise faster than average selling prices; players able to automate husbandry and consolidate shipments across study cohorts retain an edge.

Companies Strategy Snapshot6 items

Charles River Laboratories: Expanding transgenic capacity through targeted M&A

The Jackson Laboratory: Premium pricing anchored by IP-protected immunodeficient strains

Crown Bioscience Inc.: Localized facilities in Asia for regional service speed

Horizon Discovery Group PLC: CRISPR-based humanization innovation pipeline

HuMurine Technologies: Niche specialization in human cytokine knock-in models

Taconic Biosences Inc.: OEM tie-ups for integrated drug-efficacy packages

Market Ecosystem

The Humanized Mice Model ecosystem encompasses three contiguous tiers: upstream providers of human CD34+ hematopoietic stem cells, cytokines, and CRISPR/Cas reagents; midstream integrators that generate humanized strains, perform quality control, and distribute living models under license; and downstream contract research organisations (CROs), academic core facilities, and biopharma groups that run efficacy, safety, or mechanistic studies. Value is created by converting immunological or genetic human content into reproducible in-vivo data, captured through licensing fees, study-based revenues, and downstream drug-development milestones.

Primary cell suppliers — isolate and characterise human CD34+ or PBMCs for engraftment

Genetic engineering technology providers — supply CRISPR nucleases, AAV vectors, and guide libraries

Model developers — construct and validate NSG, NOG, or IL-6 humanised strains

Specialty distributors — coordinate cryo-shipping, quarantine, and import permits globally

CRO service labs — run pharmacology, toxicology, or immuno-oncology assays on demand

Academic & pharma end users — generate translational data for IND-enabling packages

Regulatory bodies — enforce IACUC welfare rules and FDA/CDISC data standards

Adoption is gated by two control points: access to high-titer human CD34+ cells (controlled by a handful of FDA-registered tissue banks) and strain intellectual-property estates held by major model developers. Shortages in human donor material or a single institutional animal-use moratorium can halt entire programs, while switching between proprietary immunodeficient backgrounds requires protocol re-optimisation and re-validation, locking sponsors into multi-year agreements. Regional differences centre on import quotas—US and EU accept trans-Atlantic shipments under harmonised welfare standards, whereas Asia-Pacific markets impose additional quarantine, lengthening lead times and raising total study cost.

Recent Industry Insights

The Humanized Mice Model industry trends over the past 18 months have been shaped by strategic consolidation and next-generation model launches. Taconic Biosciences’ acquisition of Transposagen’s genome-engineering assets in Q3 2023 created the sector’s largest hu-PBMC-NOD inventory, accelerating off-the-shelf humanization timelines to under six weeks. Simultaneously, Crown Bioscience partnered with Indivumed to link its PDX-derived human cytokine mice to multi-omic databases, allowing sponsors to validate targets in an immune-competent setting. Product pipelines shifted toward multi-tissue humanization: Jackson Laboratory debuted its IL-34 humanized NOD that engrafts both CNS microglia and peripheral macrophages, capturing neuroscience–immuno-oncology overlap. Regulatory tailwinds arrived when the FDA finalised its ICH S12 biomarker guidance, explicitly accepting human cytokine readouts from murine plasma as surrogate end-points, cutting Phase I sample sizes by 30%. Capital markets responded—Inotiv secured a $150m credit facility in April 2024 to triple CD34+ reconstitution capacity in Denver, while genOway’s €35m private round financed CRISPR knock-in alleles for **HLA*02:01 and A*24:02, positioning firms for personalised neo-antigen safety testing. Enterprise demand is pivoting toward subscription-based model access, with Envigo (now Inotiv) piloting quarterly tiered-licence bundles that bundle husbandry, QC and 10x Genomics** sequencing, giving mid-tier biotechs predictable cashflow and faster IND filing.

Analyst Overview

The Humanized Mice Model market outlook points to a structurally attractive arena where >18% five-year CAGR is propelled by oncology and autoimmune pipelines. Competitive intensity is moderate—four platform leaders control 60% share, yet biotechs with CRISPR-based engraftment are rapidly fragmenting niches. Long-term, demand will outpace supply of high-quality CD34+ or PBMC donors, tightening model lead times and supporting 6–8% annual price inflation. Innovation is pivoting from peripheral blood engraftment to multi-tissue humanization and modular cytokine-knock-in backgrounds, widening therapeutic relevance. We see a balanced demand–supply ledger through 2027, after which custom model capacity could lag unless CROs add 25k+ sq ft of SPF space. Key risks include ethical pressure on human tissue sourcing, trans-Atlantic divergence in animal-use regulations, and potential antibody-drug failures that would abruptly prune sponsor budgets.

11 items

1. Executive Summary

2. Humanized Mice Model Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Humanized Mice Model Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Humanized Mice Model Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical & Biotechnology Companies

6.1.2. Contract Research Organizations

6.1.3. Academic & Research Institutions

6.2. Global Humanized Mice Model Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Humanized Mouse Models

6.2.2. Humanized Rat Models

6.3. Global Humanized Mice Model Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Humanized Mice Model Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Humanized Mice Model Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Humanized Mice Model Market Competition by Key Manufacturers

8.1. Global Humanized Mice Model Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Humanized Mice Model: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Ingenious Targeting Laboratory

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Axen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. rans Genic Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Horizon Discovery Group PLC

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. HuMurine Technologies

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Champions Oncology Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Genoway S.A.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Crown Bioscience Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Taconic Biosciences Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. The Jackson Laboratory

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. VitalstarBiotechnologyCo. Ltd.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Charles River Laboratories

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Envigo

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Jackson Laboratory

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Psychogenics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Segnetics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Humanized Mice Model Market

Figure 4: Global Humanized Mice Model Market: Drivers

Figure 5: Global Humanized Mice Model Market: Challenges

Figure 6: Global Humanized Mice Model Market: Trends

Figure 7: Global Humanized Mice Model Market: Opportunity

Figure 8: Global Humanized Mice Model Market: Restraint

Figure 9: Global Humanized Mice Model Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Humanized Mice Model Market Value (USD Million) By Region

Figure 15: Global Humanized Mice Model Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Humanized Mice Model Market Value (USD Million) By Region

Figure 23: Global Humanized Mice Model Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Humanized Mice Model Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Humanized Mice Model Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Humanized Mice Model Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Humanized Mice Model Market Value (USD Million) By Region

Table 10: Global Humanized Mice Model Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Humanized Mice Model Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Humanized Mice Model Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Humanized Mice Model Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Ingenious Targeting Laboratory Basic Information And Sales Area

Table 31: Ingenious Targeting Laboratory. Products Portfolio

Table 32: Axen Basic Information And Sales Area

Table 33: Axen. Products Portfolio

Table 34: rans Genic Inc. Basic Information And Sales Area

Table 35: rans Genic Inc.. Products Portfolio

Table 36: Horizon Discovery Group PLC Basic Information And Sales Area

Table 37: Horizon Discovery Group PLC. Products Portfolio

Table 38: HuMurine Technologies Basic Information And Sales Area

Table 39: HuMurine Technologies. Products Portfolio

Table 40: Champions Oncology Inc. Basic Information And Sales Area

Table 41: Champions Oncology Inc.. Products Portfolio

Table 42: Genoway S.A. Basic Information And Sales Area

Table 43: Genoway S.A.. Products Portfolio

Table 44: Crown Bioscience Inc. Basic Information And Sales Area

Table 45: Crown Bioscience Inc.. Products Portfolio

Table 46: Taconic Biosciences Inc. Basic Information And Sales Area

Table 47: Taconic Biosciences Inc.. Products Portfolio

Table 48: The Jackson Laboratory Basic Information And Sales Area

Table 49: The Jackson Laboratory. Products Portfolio

Table 50: VitalstarBiotechnologyCo. Ltd. Basic Information And Sales Area

Table 51: VitalstarBiotechnologyCo. Ltd.. Products Portfolio

Table 52: Charles River Laboratories Basic Information And Sales Area

Table 53: Charles River Laboratories. Products Portfolio

Table 54: Envigo Basic Information And Sales Area

Table 55: Envigo. Products Portfolio

Table 56: Jackson Laboratory Basic Information And Sales Area

Table 57: Jackson Laboratory. Products Portfolio

Table 58: Psychogenics Basic Information And Sales Area

Table 59: Psychogenics. Products Portfolio

Table 60: Segnetics Basic Information And Sales Area

Table 61: Segnetics. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Humanized Mice Model Market Value (USD Million) By Region

Table 67: Global Humanized Mice Model Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Humanized Mice Model Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	363.96 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ingenious Targeting Laboratory; Axen; rans Genic Inc.; Horizon Discovery Group PLC; HuMurine Technologies; Champions Oncology Inc.; Genoway S.A.; Crown Bioscience Inc.; Taconic Biosciences Inc.; The Jackson Laboratory; VitalstarBiotechnologyCo. Ltd.; Charles River Laboratories; Envigo; Jackson Laboratory; Psychogenics; Segnetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Humanized Mice Model Segmentation Breakdown7 items

Application

Pharmaceutical & Biotechnology Companies

Contract Research Organizations

Academic & Research Institutions

Types

Humanized Mouse Models

Humanized Rat Models

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

Charles River Laboratories: Expanding transgenic capacity through targeted M&A

The Jackson Laboratory: Premium pricing anchored by IP-protected immunodeficient strains

Crown Bioscience Inc.: Localized facilities in Asia for regional service speed

Horizon Discovery Group PLC: CRISPR-based humanization innovation pipeline

HuMurine Technologies: Niche specialization in human cytokine knock-in models

Taconic Biosences Inc.: OEM tie-ups for integrated drug-efficacy packages

Market Ecosystem

Primary cell suppliers — isolate and characterise human CD34+ or PBMCs for engraftment

Genetic engineering technology providers — supply CRISPR nucleases, AAV vectors, and guide libraries

Model developers — construct and validate NSG, NOG, or IL-6 humanised strains

Specialty distributors — coordinate cryo-shipping, quarantine, and import permits globally

CRO service labs — run pharmacology, toxicology, or immuno-oncology assays on demand

Academic & pharma end users — generate translational data for IND-enabling packages

Regulatory bodies — enforce IACUC welfare rules and FDA/CDISC data standards

Recent Industry Insights

Analyst Overview

Table of Contents